Loading…
APRE
Aprea Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 03836J201
$0.84-2.50%Price as of Aug 29, 18:33 UTC · updated once a day, after the close
Key metrics
- Market cap
- $10.56M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.3x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.94
- ROE
- -46.15%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.59
- 52-week high
- $1.69
- 52-week low
- $0.55
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.2% over 5Y.
today you would have $7.44▼ -99.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 7 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.85 | $3.29 | $4.70 | $6.62 | $57.40 | $98.40 | $917.80 | |
| P/B | 1.3x | 0.8x | 0.9x | 1.5x | 1.0x | 1.3x | 1.3x | 7.8x |
| EPS | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88 | -$50.61 | -$93.40 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AZTRAzitra, Inc. | $0.18 | 8.8x | 1.5x | — | -256.67% | $10.72M |
| LNAILunai Bioworks Inc. | $2.37 | — | — | — | -325.46% | $10.75M |
| GDTCCytoMed Therapeutics Ltd | $0.92 | — | 2.1x | — | -50.28% | $10.89M |
| INABIn8bio Inc | $1.04 |
About the company
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
- 8
- Doylestown, United States
Company description provided by Yahoo Finance.